HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $14.18, but opened at $13.70. HUTCHMED shares last traded at $13.37, with a volume of 40,432 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.
Read Our Latest Stock Analysis on HCM
HUTCHMED Price Performance
The firm's 50 day moving average price is $15.56 and its two-hundred day moving average price is $17.53. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Hedge Funds Weigh In On HUTCHMED
Large investors have recently bought and sold shares of the business. Rhumbline Advisers raised its stake in HUTCHMED by 8.1% during the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock valued at $129,000 after acquiring an additional 564 shares during the last quarter. Renaissance Technologies LLC increased its holdings in HUTCHMED by 74.8% during the 2nd quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock valued at $2,248,000 after acquiring an additional 56,200 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in HUTCHMED by 9.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company's stock valued at $226,000 after buying an additional 1,168 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in HUTCHMED in the 2nd quarter valued at about $213,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of HUTCHMED in the second quarter valued at $279,000. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
